NOVAVAX INC Employee Count
The employee counts NOVAVAX INC states in its annual reports on SEC EDGAR, each as filed.
- 2020-12-31: Employees (as filed) 116; Filing 2021-03-01; Lease expense per employee $2.11M.
- 2019-12-31: Employees (as filed) 127; Filing 2020-03-11; Lease expense per employee $34,535.43.
- 2018-12-31: Employees (as filed) 324; Filing 2019-03-18; Lease expense per employee $15,432.10.
- 2017-12-31: Employees (as filed) 300; Filing 2018-03-14; Lease expense per employee $28,000.00.
- Available history
- 2011-12-31 to 2020-12-31
Historical Employee Count
| Date | Employees (as filed) | Filing | Lease expense per employee |
|---|---|---|---|
| 2020-12-31 | 116 | 2021-03-01 | $2.11M total lease cost |
| 2019-12-31 | 127 | 2020-03-11 | $34,535.43 total lease cost |
| 2018-12-31 | 324 | 2019-03-18 | $15,432.10 rent expense, net |
| 2017-12-31 | 300 | 2018-03-14 | $28,000.00 rent expense, net |
| 2016-12-31 | 322 | 2017-02-27 | $21,739.13 rent expense, net |
| 2015-12-31 | 369 | 2016-02-29 | $11,382.11 rent expense, net |
| 2014-12-31 | 308 full-time | 2015-02-27 | $11,688.31 rent expense, net |
| 2013-12-31 | 213 full-time | 2014-03-12 | $15,962.44 rent expense, net |
| 2012-12-31 | 137 full-time | 2013-03-12 | $23,357.66 rent expense, net |
| 2011-12-31 | 112 full-time | 2012-03-14 | $14,285.71 rent expense, net |
Headcount breakdown as filed
| Fiscal year end | Employees | Xbrl:CounterpartyName | Filing |
|---|---|---|---|
| 2019-12-31 | 127 | CatalentMarylandInc: 100 | 2020-03-11 “At December 31, 2019, we had 127 employees dedicated to our research and development programs versus 324 employees as of December 31, 2018.” |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |